Expertise in
2
conditions

Dr. Mercedes Porosnicu

Internal Medicine
Carenet Inc.
2311 Lewisville Clemmons Rd, 
Clemmons, NC 
Accepting New Patients
Expertise in
2
conditions
Carenet Inc.
2311 Lewisville Clemmons Rd, 
Clemmons, NC 

Overview

Mercedes Porosnicu is a primary care provider, practicing in Internal Medicine in Clemmons, North Carolina.

Dr. Porosnicu is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Nasopharyngeal Carcinoma, Anaplastic Thyroid Cancer, Bone Marrow Aspiration, and Gamma Knife Radiosurgery.

She is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 8 clinical trials. Dr. Porosnicu is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in NC

Hospital Affiliations

High Point Regional Health System
North Carolina Baptist Hospital

Languages Spoken

English
Romanian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Carenet Inc.
2311 Lewisville Clemmons Rd, Clemmons, NC 27012

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer
Enrollment Status: Completed
Publish Date: November 19, 2025
Intervention Type: Drug, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery
Enrollment Status: Terminated
Publish Date: March 17, 2025
Intervention Type: Biological, Other, Procedure
Study Drug: Durvalumab
Study Phase: Early Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy
Enrollment Status: Terminated
Publish Date: March 22, 2023
Intervention Type: Other, Drug
Study Drugs: Bupropion Hydrochloride, Nicotine Replacement, Varenicline
Study Phase: Early Phase 1
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Withdrawn
Publish Date: December 19, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

36 Total Publications

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.
Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.
Journal: JAMA otolaryngology-- head & neck surgery
Published: June 18, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Alain G. Bertoni
Internal Medicine
Expertise in
14
conditions
Dr. Alain G. Bertoni
Internal Medicine

Office

1 S Hawthorne Rd, 
Winston Salem, NC 
 (6.2 miles away)
336-716-2011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alain Bertoni is a primary care provider, practicing in Internal Medicine in Winston Salem, North Carolina. Dr. Bertoni is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Atherosclerosis, Type 2 Diabetes (T2D), Heart Failure, and Maturity Onset Diabetes of the Young. Dr. Bertoni is currently accepting new patients.

Expertise in
5
conditions
Dr. Jamy D. Ard
Internal Medicine
Expertise in
5
conditions
Dr. Jamy D. Ard
Internal Medicine

Atrium Health Wake Forest Baptist Travel Medicine-Country Club

4614 Country Club Rd, 
Winston Salem, NC 
 (4.0 miles away)
336-713-0708
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jamy Ard is a primary care provider, practicing in Internal Medicine in Winston Salem, North Carolina. Dr. Ard is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Obesity, Obesity in Children, Type 2 Diabetes (T2D), Metabolic Syndrome, and Sleeve Gastrectomy. Dr. Ard is currently accepting new patients.

Expertise in
179
conditions
Dr. Imran P. Haque
Internal Medicine
Expertise in
179
conditions
Dr. Imran P. Haque
Internal Medicine
Before you request

Horizon Internal Medicine PLLC

1380 Eastchester Dr Ste 105, 
High Point, NC 
 (22.2 miles away)
336-610-1300
Languages Spoken:
English, Hindi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Imran Haque is a primary care provider, practicing in Internal Medicine in High Point, North Carolina. Dr. Haque is highly rated in 179 conditions, according to our data. His clinical expertise encompasses Heart Murmurs, Vitamin B12 Deficiency, Type 2 Diabetes (T2D), and Nasal Flaring. Dr. Haque is currently accepting new patients.

Frequently Asked Questions about Dr. Mercedes Porosnicu

How do I make an appointment with Dr. Mercedes Porosnicu?

You can book an appointment with Dr. Mercedes Porosnicu by calling their office at 336-713-1717. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mercedes Porosnicu a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mercedes Porosnicu is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mercedes Porosnicu specialize in?

While Dr. Mercedes Porosnicu is a Internal Medicine, they have specific expertise in Neuroendocrine Tumor, Nasopharyngeal Carcinoma, and Anaplastic Thyroid Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mercedes Porosnicu participate in research or clinical trials?

Yes. Dr. Mercedes Porosnicu has published 36 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Mercedes Porosnicu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mercedes Porosnicu accept my insurance?

Dr. Mercedes Porosnicu accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 336-713-1717 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Porosnicu's expertise for a condition
ConditionClose
      View All 28 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile